相关实验视频

Updated: Jun 11, 2025

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes

Published on: April 10, 2015

复合物与阿比拉酸作为抗增殖剂

Anastasia A Antonets¹, Ekaterina V Spitsyna¹, Vladimir Yu Tyurin²

¹Department of Chemistry, M. V. Lomonosov Moscow State University, Leninskie Gory 1/3, 119991 Moscow, Russia.

Journal of inorganic biochemistry

|October 9, 2024

概括

这项研究开发了与阿比拉乙酸结合的新型复合物,具有双重抗癌作用. 与单独的阿比拉酸相比,最活跃的化合物显示出更好的抗扩散和亡诱导.

科学领域:

药用化学医学化学
癌症生物学癌症生物学
无机化学无机化学

背景情况:

开发新型多式抗癌药物对于克服耐药性和提高治疗疗效至关重要.
复合物和阿比拉酸具有明显的抗瘤特性.
结合这些药物为癌症治疗提供了一种协同的方法.

研究的目的:

为了合成和描述与阿比拉乙酸结合的新型鲁复合物.
评估这些新型化合物对癌细胞的抗增殖活性和作用机制.
评估这些双重作用剂作为下一代抗癌疗法的潜力.

主要方法:

合成与阿比拉乙酸结合的鲁复合物.
在体外对各种癌细胞系和原发性纤维细胞进行抗增殖试验.
实时细胞分析以确定对细胞增殖的剂量依赖性影响.
流式细胞计量用于研究细胞死亡的机制,特别是诱导细胞亡.

主要成果:

合成的鲁-阿比拉酸联合体对癌细胞表现出显著的抗增殖活性.
观察到显著的选择性,对初级纤维细胞的毒性降低.
化合物二化物 (η6-p-cymene) (abiraterone乙酸) (II) 与单独的abiraterone乙酸相比,显示出增强的抗扩散作用.
流细胞测量证实,最活跃的化合物有效诱导癌细胞的亡.

结论:

与阿比拉酸结合的鲁复合物代表着有前途的多式模式抗癌剂.
增强的疗效和诱导亡的特性突出显示了它们在临床开发中的潜力.
这种双重行动策略为癌症治疗提供了一个新的治疗途径.

关键词:

阿比拉特龙乙酸的使用情况它具有抗癌活性.反扩散活动的反扩散活动.电化学行为电化学行为这是一个RTCA.化合物; 化合物;

更多相关视频

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Published on: October 26, 2017

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...